Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. Announce Filing of New Drug Submission for Silenor®

Published: Feb 23, 2012

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor® (doxepin) for the treatment and symptomatic relief of insomnia.

Back to news